Results 241 to 250 of about 26,068 (276)

Aldosterone, Mineralocorticoid Receptor and the Metabolic Syndrome:Role of the Mineralocorticoid Receptor Antagonists

Current Vascular Pharmacology, 2012
Several lines of evidence suggest a detrimental effect of aldosterone excess on the development of metabolic alterations. Glucose metabolism derangements due to aldosterone action are frequently observed not only in patients with primary aldosteronism but also in patients with obesity. A contribution to the hyperaldosteronism observed in obese subjects
Ronconi, Vanessa, Turchi, Federica, Appolloni, Gloria, di Tizio, Valentina, BOSCARO, MARCO, Giacchetti, Gilberta   +5 more
openaire   +3 more sources

Emerging cardiovascular indications of mineralocorticoid receptor antagonists

Trends in Endocrinology & Metabolism, 2015
Mineralocorticoid receptor (MR) antagonism is a well-established treatment modality for patients with hypertension, heart failure, and left ventricular systolic dysfunction (LVSD) post-myocardial infarction (MI). There are emerging data showing potential benefits of MR antagonists in other cardiovascular conditions.
Parviz, Yasir, Iqbal, Javaid, Pitt, Bertram, Adlam, David, Al-Mohammad, Abdallah, Zannad, Faiez   +5 more
openaire   +2 more sources

Adverse Effects of Mineralocorticoid Receptor Antagonist Administration

Current Pharmaceutical Design, 2019
Background: Mineralocorticoid receptor antagonists consist of a class of drugs with pleiotropic beneficial effects in several cardiovascular diseases. However, physicians frequently overlook their use due to the adverse effects of such agents. Objectives: To determine the adverse effects of mineralocorticoid receptor antagonists and to suggest ...
Manolis S, Kallistratos, Andreas, Pittaras, Iakovos, Theodoulidis, Charris, Grassos, Leonidas E, Poulimenos, Athanasios J, Manolis   +5 more
openaire   +2 more sources

Mineralocorticoid receptor antagonists (MRAs)

2014
Abstract The final process in the renin–angiotensin–aldosterone system (RAAS) is the production of the mineralocorticoid aldosterone in the adrenal glands. Aldosterone has an important role in the pathophysiology of heart failure, and concentrations of aldosterone are 20-fold higher in patients with HF compared to normal individuals ...
Roy S. Gardner, Theresa A. McDonagh, Niki L. Walker   +2 more
openaire   +1 more source

Drug Insight: eplerenone, a mineralocorticoid-receptor antagonist

Nature Clinical Practice Endocrinology & Metabolism, 2008
Increasing recognition of the role of aldosterone in cardiovascular disease has been supported by a significant body of evidence from animal models. This evidence has been translated into clinical practice, and large-scale, randomized, placebo-controlled trials have confirmed the beneficial effects of mineralocorticoid blockade in patients with heart ...
McManus, Frances, McInnes, Gordon T, Connell, John M C   +2 more
openaire   +3 more sources

Mineralocorticoid receptor antagonists in kidney transplantation

European Journal of Clinical Investigation
AbstractBackgroundThe fundamental role of the renin–angiotensin–aldosterone system in the pathophysiology of chronic kidney disease, congestive heart failure, hypertension and proteinuria is well established in pre‐clinical and clinical studies. Mineralocorticoid receptor antagonists are among the primary options for renin–angiotensin–aldosterone ...
Mehmet Kanbay, Sidar Copur, Berk Mizrak, Francesca Mallamaci, Carmine Zoccali   +4 more
openaire   +2 more sources

The cardioprotective effects of mineralocorticoid receptor antagonists

Pharmacology & Therapeutics, 2014
Despite state-of-the-art reperfusion therapy, morbidity and mortality remain significant in patients with an acute myocardial infarction. Therefore, novel strategies to limit myocardial ischemia-reperfusion injury are urgently needed. Mineralocorticoid receptor (MR) antagonists are attractive candidates for this purpose, since several clinical trials ...
van den Berg, T.N.A., van den Berg, T.N.A., Rongen, G.A.P.J.M., Rongen, G.A.P.J.M., Rongen, G.A.P.J.M., Frohlich, G.M., Deinum, J., Deinum, J., Hausenloy, D.J., Riksen, N.P., Riksen, N.P., Riksen, N.P., Riksen, N.P.   +12 more
openaire   +3 more sources

Mineralocorticoid receptor antagonists—pharmacodynamics and pharmacokinetic differences

Current Opinion in Pharmacology, 2016
Mineralocorticoid receptor antagonists (MRAs) are best known as potassium-sparing diuretics due to their blockade of aldosterone action in renal epithelial tissues. They are also beneficial for the treatment of heart failure, primarily due to effects in non-epithelial tissues. Currently there are only two steroidal MRAs that have been approved for use;
Jun, Yang, Morag J, Young
openaire   +2 more sources

Role of mineralocorticoid receptor antagonists in kidney diseases

Drug Development Research, 2020
AbstractMineralocorticoid receptor (MR) antagonists, for example, spironolactone and eplerenone, are in clinical use to treat hypertension. Increasing evidence suggests that mineralocorticoid receptor activation causes the pathogenesis and progression of chronic kidney disease.
Vishal Patel, Amit Joharapurkar, Mukul Jain   +2 more
openaire   +2 more sources

The renal effects of mineralocorticoid receptor antagonists

International Journal of Cardiology, 2015
Beyond its well known classic effects on renal water and electrolytes metabolism, an increasing amount of experimental and clinical evidence suggests that aldosterone contributes to the pathogenesis and progression of kidney disease. The binding of aldosterone on epithelial and non-epithelial cells of the kidney induces many deleterious effects, such ...
Stefano, Bianchi, Valentina, Batini, Roberto, Bigazzi   +2 more
openaire   +2 more sources